These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 24314219)

  • 1. [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
    Guo X; Liu TS; Yu YY; Zhou YH; Chen Y; Zhuang RY; Cui YH
    Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):604-7. PubMed ID: 24314219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer.
    Miyo M; Kato T; Yoshino T; Yamanaka T; Bando H; Satake H; Yamazaki K; Taniguchi H; Oki E; Kotaka M; Oba K; Miyata Y; Muro K; Komatsu Y; Baba H; Tsuji A
    BMC Cancer; 2020 Jul; 20(1):687. PubMed ID: 32703200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.
    Stein A; Atanackovic D; Hildebrandt B; Stübs P; Brugger W; Hapke G; Steffens CC; Illerhaus G; Bluemner E; Stöhlmacher J; Bokemeyer C
    Br J Cancer; 2015 Sep; 113(6):872-7. PubMed ID: 26335608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab-induced nasal septal perforation: incidence of symptomatic, confirmed event(s) in colorectal cancer patients.
    Ramiscal JA; Jatoi A
    Acta Oncol; 2011 May; 50(4):578-81. PubMed ID: 21108568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study.
    Yuki S; Yamazaki K; Sunakawa Y; Taniguchi H; Bando H; Shiozawa M; Nishina T; Yasui H; Kanazawa A; Ando K; Horita Y; Goto M; Okano N; Moriwaki T; Satoh T; Tsuji A; Yamashita K; Asano C; Abe Y; Nomura S; Yoshino T
    Clin Colorectal Cancer; 2024 Jun; 23(2):147-159.e7. PubMed ID: 38331650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin.
    Luo W; Liao WJ; Ma L; Huang YT; Shi M; Wen Q; Wang XN
    Cancer Immunol Immunother; 2010 Feb; 59(2):247-56. PubMed ID: 19652968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer.
    Kemeny NE; Jarnagin WR; Capanu M; Fong Y; Gewirtz AN; Dematteo RP; D'Angelica MI
    J Clin Oncol; 2011 Mar; 29(7):884-9. PubMed ID: 21189384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer.
    Altomare I; Bendell JC; Bullock KE; Uronis HE; Morse MA; Hsu SD; Zafar SY; Blobe GC; Pang H; Honeycutt W; Sutton L; Hurwitz HI
    Oncologist; 2011; 16(8):1131-7. PubMed ID: 21795432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of atezolizumab and bevacizumab combination regimens in patients with hepatocellular carcinoma and lung cancer taking direct oral anticoagulants.
    Nakabori T; Kunimasa K; Kawabata M; Higashi S; Mukai K; Kawamura T; Inoue T; Tamiya M; Nishino K; Ohkawa K
    Cancer Med; 2024 Jun; 13(12):e7430. PubMed ID: 38924675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal Maintenance Strategy for First-Line Oxaliplatin-Containing Therapy with or without Bevacizumab in Patients with Metastatic Colorectal Cancer: A Meta-Analysis.
    Moriwaki T; Gosho M; Sugaya A; Yamada T; Yamamoto Y; Hyodo I
    Cancer Res Treat; 2021 Jul; 53(3):703-713. PubMed ID: 33285056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-angiogenic therapy with contrast-enhanced ultrasound in colorectal cancer patients with liver metastasis.
    Wu Z; Yang X; Chen L; Wang Z; Shi Y; Mao H; Dai G; Yu X
    Medicine (Baltimore); 2017 May; 96(20):e6731. PubMed ID: 28514289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC.
    Bando H; Kotani D; Satake H; Hamaguchi T; Shiozawa M; Kotaka M; Masuishi T; Yasui H; Kagawa Y; Komatsu Y; Oki E; Yamamoto Y; Kawakami H; Misumi T; Taniguchi H; Yamazaki K; Muro K; Yoshino T; Kato T; Tsuji A
    Med; 2024 Jun; ():. PubMed ID: 38901425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Bevacizumab Combined with Albumin-Bound Paclitaxel in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer.
    Liu B; An R; Yu J
    J BUON; 2019; 24(6):2303-2309. PubMed ID: 31983098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of bevacizumab and interferon-α2b in ocular melanoma.
    Guenterberg KD; Grignol VP; Relekar KV; Varker KA; Chen HX; Kendra KL; Olencki TE; Carson WE
    Am J Clin Oncol; 2011 Feb; 34(1):87-91. PubMed ID: 20458209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study.
    Li H; Qin S; Liu Y; Chen Z; Ren Z; Xiong J; Meng Z; Zhang X; Wang L; Zhang X; Zou J
    Drug Des Devel Ther; 2021; 15():1873-1882. PubMed ID: 33976538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VIC Regimen (Vemurafenib/Irinotecan/Cetuximab) Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Unresectable or Metastatic Colorectal Cancer in Asian Patients: A Prospective Cohort Study.
    Chen Y; Zhu D; Yu Y; Chang W; Ye L; Feng Q; Xu P; Chen M; Ji M; Wei Y; Liu T; Xu J
    Clin Colorectal Cancer; 2024 May; ():. PubMed ID: 38845274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unsupported off-label chemotherapy in metastatic colon cancer.
    de Souza JA; Polite B; Perkins M; Meropol NJ; Ratain MJ; Newcomer LN; Alexander GC
    BMC Health Serv Res; 2012 Dec; 12():481. PubMed ID: 23272659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan-induced immune thrombocytopenia.
    Mirtsching BC; George JN; Aster RH; Curtis BR
    Am J Med Sci; 2014 Feb; 347(2):167-9. PubMed ID: 24472819
    [No Abstract]   [Full Text] [Related]  

  • 19. A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection.
    Osterlund P; Peltonen R; Alanko T; Bono P; Isoniemi H
    Onco Targets Ther; 2014; 7():1177-84. PubMed ID: 25061319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma.
    Yamaba S; Imai Y; Sugawara K; Uchida Y; Fuchigami A; Uchiya H; Nakayama N; Mochida S
    PLoS One; 2024; 19(4):e0298770. PubMed ID: 38687817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.